The observation that CT26-controlling immune responses induced in vaccinated mice were likewise able to control 4T1 wt tumours (a more stringent tumour model) highlights the increased efficacy and broad potential of our modified VLVs targeting ERV epitopes that are shared in distinct cancers. This evidence concerns the gene DDX53 and cancer.